VJOncology is committed to improving our service to you

ASCO 2018 | PROPHECY trial: AR-V7 CTCs as a biomarker in mCRPC

VJOncology is committed to improving our service to you

Andrew Armstrong

Andrew Armstrong, MD, from Duke University, Durham, NC, speaks from the 2018 American Society of Oncology (ASCO) Annual Meeting, held in Chicago, IL. Dr Armstrong shares details of the PROPHECY trial (NCT02269982), which is investigating AR-V7 on circulating tumor cells as a prospective predictor in men with metastatic castration-resistant prostate cancer (mCRPC).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter